Overview
Demand for transdermal estrogen patches has accelerated sharply over the past two years, producing persistent local shortages and prompting patients to search multiple pharmacies and alter treatment regimens. Industry participants, clinicians and patients describe a market still adjusting to new patterns of use that began to accelerate after the U.S. Food and Drug Administration publicly changed its stance on hormone replacement therapy last year.
Why shortages have emerged
More than 1 million U.S. women enter menopause each year, and over the past two years a growing share have gravitated toward estrogen patches to manage symptoms such as hot flashes, mood swings and sleep disturbances. Social media conversations and changing clinical guidance have influenced perceptions of the safety and benefits of these therapies.
The FDA began publicly praising hormone replacement therapy as "lifesaving" in July of last year and removed a longstanding safety warning in November. That regulatory messaging was followed by measurable increases in use: Truveta, a health data analytics company, reported a 26% jump in patch use through February, and in a separate analysis found a 184% increase in estrogen patch use since 2023 across its electronic health record database covering more than 130 million patients. Truveta also reported a 122% rise in vaginal cream HRT use over the same period. By February 2026, roughly 5 out of every 100 women aged 45-54 who had received any medical prescription had been prescribed estrogen-based HRT, about double the rate observed in 2023.
Immediate effects on patients
Women seeking patches report practical obstacles: pharmacy-hopping, changing brands or dosages, and longer lead times for online orders. Interviews with six patients, three telehealth companies and six industry experts indicate many are adjusting treatments or facing interruptions. Doctors caution that abrupt discontinuation can cause a recurrence of menopausal symptoms, while switching brands or formulations can introduce different side effects.
Amy Satterlund, 50, a product manager from Fort Pierce, Colorado, said she has used the patch for about 18 months but recently struggled to refill prescriptions. She described having to plan for intermittent availability at CVS locations and experiencing long waits through online pharmacy Cost Plus Drugs. "I do get nervous if I were unable to get my prescription refilled, that side effects or that the symptoms of perimenopause would come back," she said.
Industry and government responses
Manufacturers and government officials say they are working to address the supply gap. A Sandoz spokesperson said, "When the FDA removed the safety warning in November, it created unprecedented demand that cannot fully be met at present," and noted the company has shipped additional supplies to the U.S. to help ease shortages. An Andrew Nixon, a spokesman for the U.S. Health and Human Services Department, said the agency is coordinating with companies to support efforts to boost patch supply.
CVS Health told reporters that manufacturers have been unable to deliver sufficient quantities in recent weeks. Cost Plus Drugs said it has added supply to match expanding demand but had not been told by suppliers that shortages would last for an extended period.
Data from telehealth and EHR sources
Telehealth provider HRT Club, which helps patients access hormone therapies and physicians, reported patch sales rose 150% after the FDA's November actions. Truveta's analysis, using its electronic health record database spanning all 50 states, is the basis for the larger reported increases in HRT utilization.
Manufacturing limitations
Estrogen patches are generally generic products with low profit margins. Industry experts and clinicians say these economics reduce manufacturers' incentives to rapidly expand production capacity. Building new production lines or facilities can take years, and long-term contractual arrangements for supply can constrain rapid adjustments to sudden demand shifts.
Major makers named in industry commentary include Amneal, Zydus, Sandoz, Noven and Viatris. The American Society of Health-System Pharmacists reports that each of these companies has some doses in shortage. Amneal and Viatris said they are trying to increase supply; Zydus and Noven did not respond to requests for comment.
Dr. Gillian Goddard, adjunct assistant professor at the NYU Grossman School of Medicine, noted the scale of the recent change: "For 20 years, less than 5% of women took hormone therapy. Now those numbers are growing... and scaling up production of medications is not as easy as it might seem."
Possible mitigation and oversight
Clinicians and health-system leaders point to options the FDA could use to reduce future shortages, including requirements for more diversified and redundant supply chains, mandated minimum inventories, and proactive inventory monitoring systems. Dr. Mary Rosser, director of Integrated Womens Health at Columbia University, said the FDA does have mechanisms to mitigate shortages but that the agency declined to comment on specific measures under consideration. "People have waited a long time to make a decision... about whether they want to use hormones," Rosser said. "Then they make the decision and then they cant get them."
Clinical consequences and patient behavior
Evidence from interviews and clinicians indicates patients are responding to limited availability in several ways: seeking different pharmacies, lowering or changing doses, switching brands or changing to other types of therapy. Each workaround carries clinical trade-offs. Physicians warn that stopping therapy abruptly can bring back symptoms, while brand or formulation changes can introduce side effects that patients did not experience on their original regimen.
Outlook
Industry sources and some experts told interviewers that shortages could persist for up to three years if production capacity cannot be scaled in time. Government coordination with manufacturers is ongoing, and several pharmaceutical producers said they are attempting to increase output, but systemic manufacturing constraints and the economics of low-margin generics remain central challenges.
Key points
- Regulatory shifts from the FDA in mid-to-late 2023 and November drove a sharp rise in demand for estrogen patches, with Truveta reporting a 26% jump through February and a reported 184% increase since 2023 in its dataset.
- Patients are experiencing access problems - pharmacy shortages, supply delays and forced changes in dosing or products - while manufacturers face long lead times to increase production; sectors affected include pharmaceutical manufacturing and retail pharmacy distribution.
- Major generics makers including Amneal, Zydus, Sandoz, Noven and Viatris have some doses in shortage, and government agencies are coordinating with industry to try to expand supplies.
Risks and uncertainties
- Supply risk - Manufacturing capacity and the low-margin nature of generic patches limit rapid scale-up, potentially prolonging shortages; this directly affects pharmaceutical manufacturers and pharmacy supply chains.
- Clinical risk - Patients who abruptly stop or frequently switch HRT products may experience returning symptoms or new side effects; this impacts clinical services, telehealth providers and patient outcomes.
- Policy uncertainty - It is unclear which regulatory interventions, if any, the FDA will impose to mandate inventories or diversify supply chains, and the agency declined to comment on such options.